Fig. 1 · Structure
Documents & Downloads
HRX-0233
MAP2K4 Inhibitor
HRX-0233 is a small-molecule inhibitor of MAP2K4, known for its ability to effectively induce tumor shrinkage in H358 KRASG12C-mutant non-small cell lung cancer models with minimal toxicity. This compound prevents the feedback activation of receptor tyrosine kinases when used in conjunction with KRAS inhibitors, leading to more sustained and comprehensive inhibition of MAPK signaling pathways. HRX-0233 is a valuable tool for research applications focused on AR-negative prostate cancer, as well as lung and colon cancers.
In Stock
Free Aliquoting for Your Order
Tell us your preferred amount per vial. We’ll confirm the options.
Specifications
| Manufacturer | Adooq Bioscience |
|---|---|
| Actions | Inhibitor |
| CAS Number | 2409140-12-9 |
| Applications | MAP2K4 Inhibitor |
| Formula | C24H21F2N5O3S |
| Molecular Weight | 497.52 |
| SMILES | O=C(C1=CNC2=NC=C(C3=CN=C(C4CC4)N=C3)C=C21)C5=CC=C(C(NS(=O)(CCC)=O)=C5F)F |
Storage & Solubility
In Vitro Solubility
Reported Solubility
No reported solubility data are available for this product.
Preparing Stock Solutions
| Concentration | |
|---|---|
Values use four significant digits. Prepare to the final solution volume; this is not the volume of solvent to add.
Stock preparation is unavailable for this product molecular weight.
Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.
Storage
Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.